SCHEMBL23705171

SCHEMBL23705171

CO[C@@H]1O[C@H](COCc2ccccc2)[C@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR1 P30872 1/20 0.56
SSTR2 P30874 1/20 0.56
SSTR4 P31391 1/20 0.56
SSTR3 P32745 1/20 0.56
SSTR5 P35346 1/20 0.56
PTPN1 P18031 8/20 0.47
PTPN2 P17706 4/20 0.47
NT5E P21589 1/20 0.47
BCHE P06276 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
GJB2 P29033 1/20 0.45
CDC25B P30305 5/20 0.44
FGF1 P05230 2/20 0.43
FGF2 P09038 2/20 0.43
VEGFA P15692 2/20 0.43
HPSE Q9Y251 2/20 0.43
PTPN6 P29350 2/20 0.43
PTPN11 Q06124 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1893390 1.00 SSTR1 (0.56) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL16949458 1.00 SSTR1 (0.56) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL23705173 1.00 SSTR1 (0.56) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1893392 1.00 SSTR1 (0.56) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL17453459 0.99 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL17039881 0.99 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL5981881 0.99 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL21837297 0.99 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL21880793 0.99 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL8992058 0.96 SSTR1 (0.56) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339541-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-11-06 US disclosed
US-20250213699-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-07-03 US disclosed
US-12290568-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2025-05-06 US disclosed
US-12280116-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2025-04-22 US disclosed
US-20240424108-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-12-26 US disclosed
US-12128106-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2024-10-29 US disclosed
US-20240307546-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-09-19 US disclosed
US-12076408-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2024-09-03 US disclosed
US-20240245785-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-25 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20230097256-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2023-03-30 US disclosed
EP-4097138-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS Avila Therapeutics, Inc. (US) 2022-12-07 EP disclosed
CN-115066438-A ASGPR binding compounds for degrading extracellular proteins 阿维拉治疗公司 2022-09-16 CN disclosed
WO-2022035997-A1 IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS AVILAR THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed
WO-2021155317-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-20250339541-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-20240424108-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-20250213699-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-20230097256-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-12076408-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-12128106-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-12290568-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-12280116-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-20240245785-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885
US-20240307546-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A SSTR1 1952/4885SSTR2 2585/4885SSTR4 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.